Medical Care Technologies Inc Stock Price, News & Analysis

Medical Care Technologies (OTC Pink:MDCE) has secured access to the International Skin Imaging Collaboration (ISIC) Archive, one of the world's largest public skin cancer image databases. The archive contains over 70,000 dermoscopic images with expert annotations across various skin tones and cancer types.

This database will be used to train MDCE's AI software for detecting and classifying melanoma and other skin cancers. With skin cancer being the most common cancer globally (1.5 million new cases annually), this development aims to improve early detection capabilities worldwide.

The company is currently integrating the ISIC data into its machine learning pipeline and exploring additional collaborations to expand its training image database as it progresses toward clinical trials and commercialization.

Medical Care Technologies Inc. (OTC PINK:MDCE) announced a leadership transformation under CEO Marshall Perkins, following his remarkable recovery from advanced bone cancer and vitiligo in early 2025. After months of hospitalization and a challenging recovery process that affected his vertebrae and mobility, Perkins has made a full recovery.

Now recovered, Perkins is leading MDCE's initiatives in healthcare innovation, working with a team of medical experts, students, and technology innovators to develop preventative healthcare solutions. The company aims to create value for both patients and shareholders through its focus on healthcare monitoring and optimization technologies.

Medical Care Technologies (OTC:MDCE) has launched an innovative AI Facial Health Risk Estimator designed to detect diabetic retinopathy in its early stages. The technology analyzes facial images to identify retinal abnormalities such as microaneurysms, hemorrhages, and vascular leakage, offering a non-invasive screening solution.

CEO Marshall Perkins emphasized that this AI-powered system aims to address the challenge of late diagnosis in diabetic retinopathy, which is a leading cause of preventable blindness globally. The technology promises to improve accessibility to early screening and enhance patient outcomes through early detection.

Medical Care Technologies (OTC:MDCE) has enhanced its AI Facial Health Risk Estimator platform to include detection capabilities for glaucoma and cataracts. The expanded platform now analyzes high-resolution facial and ocular images to identify corneal opacity, lens clouding, and early optic nerve changes.

The integration creates a comprehensive preventive care solution by combining eye health monitoring with existing systemic and dermatological metrics. CEO Marshall Perkins emphasized the platform's holistic approach to early detection of vision-threatening conditions.

Medical Care Technologies (OTC:MDCE) has announced the development of an innovative AI Facial Health Risk Estimator for early diabetes detection. The technology analyzes facial biomarkers including skin tone irregularities, microvascular patterns, and elasticity loss to predict Type 2 diabetes risk before clinical diagnosis.

The non-invasive system uses predictive algorithms to assess diabetes susceptibility through facial analysis, potentially enabling earlier interventions and better patient outcomes, according to CEO Marshall Perkins.

Medical Care Technologies (OTC:MDCE) has unveiled its innovative AI Facial Health Risk Estimator, a technology designed to detect early cardiovascular disease risks through advanced facial imaging analysis.

The system employs deep neural networks to analyze biometric markers including micro-wrinkle density, skin elasticity, and tone variations. By comparing biological age against chronological age, the platform can identify cardiovascular predisposition before clinical symptoms appear, offering a non-invasive alternative to traditional testing methods.

Medical Care Technologies (OTC:MDCE) has unveiled an innovative AI platform for detecting squamous cell carcinoma (SCC), the second most common form of skin cancer. The technology employs advanced machine learning classifiers to identify early warning signs that might be missed during self-examinations.

The AI system utilizes edge-detection algorithms and keratin pattern recognition to identify various SCC indicators including rough patches, persistent lesions, and early ulcerations. A key feature is its ability to differentiate SCC from precancerous conditions through longitudinal comparison modeling, tracking lesion evolution across the entire body.

Medical Care Technologies (OTC:MDCE) has launched an innovative AI platform designed for early detection of basal cell carcinoma (BCC), the most common type of skin cancer. The platform enables at-home screening and monitoring through advanced texture and reflectance analysis technology.

The AI system features sophisticated capabilities including pearly nodule identification, vascular pattern recognition, ulceration tracking, and pixel-level texture classification to distinguish between benign growths and potential carcinomas. This technology aims to address the limited access to dermatology services by providing accessible, non-invasive screening solutions.

Medical Care Technologies (OTC:MDCE) has unveiled a groundbreaking AI platform for early melanoma detection. The technology leverages deep learning algorithms trained on millions of dermatoscopic and clinical images to analyze key melanoma risk factors including asymmetry, border irregularities, color variations, diameter, and evolution monitoring.

The AI system creates longitudinal profiles of moles and lesions, flagging anomalies before progression. This advancement is particularly significant as melanoma, while representing only 1% of skin cancers, causes the majority of skin cancer deaths. When detected early, melanoma survival rates exceed 95%.